Related Experiment Video
Updated: Aug 7, 2026
06:32
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Medulloblastoma
1Department of Neurosurgery, Hua Shan Hospital, Shanghai Medical University, Shanghai 200040, China.
Chinese Medical Journal
|October 12, 2001
Summary
Medulloblastoma treatment involving surgery and radiotherapy improves survival rates. However, long-term survival for medulloblastoma patients remains limited, with recurrence often occurring within 3.5 years.
Area of Science:
- Neuro-oncology
- Pediatric Oncology
- Surgical Oncology
Background:
- Medulloblastoma is a primary brain tumor originating in the cerebellum.
- It is the most common malignant brain tumor in children, but can also occur in adults.
Purpose of the Study:
- To analyze the diagnosis, treatment strategies, and prognosis of medulloblastoma in pediatric and adult populations.
- To evaluate the effectiveness of different therapeutic interventions and their impact on survival rates.
Main Methods:
- Retrospective review of 80 pathologically confirmed medulloblastoma cases diagnosed between 1984 and 1995.
- Multivariate analysis of surgical, radiotherapeutic, and chemotherapeutic effects on patient survival.
Main Results:
- The study included 42 males and 38 females with average ages of 9.1 years (children) and 25.1 years (adults).
- Overall 5-year and 10-year survival rates were 50.5% and 27.89%, respectively. Adults had a higher 5-year survival rate than children.
- Recurrence or metastasis led to death in 32 patients, with a mean recurrence time of 3.5 years.
Conclusions:
- Surgical tumor removal combined with postoperative radiotherapy is crucial for improving medulloblastoma patient survival.
- Craniospinal radiotherapy significantly enhances survival outcomes.
- Long-term survival for medulloblastoma patients is limited, aligning with Collins' law regarding the period of risk.
